Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Depreciation & Amortization (CF) (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $77000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 61.31% to $77000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $499000.0, a 26.07% decrease, with the full-year FY2024 number at $723000.0, up 15.13% from a year prior.
  • Depreciation & Amortization (CF) was $77000.0 for Q3 2025 at Plus Therapeutics, roughly flat from $77000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $199000.0 in Q3 2024 to a low of $77000.0 in Q2 2025.
  • A 5-year average of $147375.0 and a median of $156500.0 in 2022 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 67.05% in 2022, then tumbled 61.31% in 2025.
  • Plus Therapeutics' Depreciation & Amortization (CF) stood at $88000.0 in 2021, then skyrocketed by 80.68% to $159000.0 in 2022, then dropped by 5.03% to $151000.0 in 2023, then skyrocketed by 31.79% to $199000.0 in 2024, then crashed by 61.31% to $77000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Depreciation & Amortization (CF) are $77000.0 (Q3 2025), $77000.0 (Q2 2025), and $146000.0 (Q1 2025).